Docusign (NASDAQ:DOCU) Insider Sells $119,274.21 in Stock

Docusign Inc. (NASDAQ:DOCU) insider Robert Chatwani sold 1,683 shares of the business’s stock in a transaction on Monday, December 15th. The stock was sold at an average price of $70.87, for a total transaction of $119,274.21. Following the completion of the sale, the insider owned 68,496 shares in the company, valued at $4,854,311.52. This represents a 2.40% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link.

Robert Chatwani also recently made the following trade(s):

• On Wednesday, December 17th, Robert Chatwani sold 13,818 shares of Docusign stock. The stock was sold at an average price of $68.33, for a total transaction of $944,183.94.
• On Thursday, December 11th, Robert Chatwani sold 983 shares of Docusign stock. The stock was sold at an average price of $68.62, for a total value of $67,453.46.

Docusign Price Performance

NASDAQ DOCU traded up $0.21 during midday trading on Wednesday, hitting $67.79. 2,888,432 shares of the company traded hands, compared to its average volume of 2,759,651. The company has a market cap of $13.58 billion, a PE ratio of 47.41, a price-to-earnings-growth ratio of 3.42 and a beta of 0.98. The company’s 50-day simple moving average is $68.97 and its 200-day simple moving average is $74.21. Docusign Inc. has a 52 week low of $63.41 and a 52 week high of $99.71.

Analyst Ratings Changes

Several equities research analysts have weighed in on the company. Wall Street Zen raised Docusign from a “hold” rating to a “buy” rating in a research report on Saturday, September 13th. Evercore ISI cut their price objective on Docusign from $92.00 to $80.00 and set an “in-line” rating for the company in a research report on Friday, December 5th. Robert W. Baird cut their target price on shares of Docusign from $90.00 to $75.00 and set a “neutral” rating on the stock in a research note on Friday, December 5th. JPMorgan Chase & Co. dropped their target price on Docusign from $80.00 to $78.00 and set a “neutral” rating on the stock in a report on Friday, December 5th. Finally, Argus reaffirmed a “hold” rating on shares of Docusign in a report on Monday, September 8th. Six investment analysts have rated the stock with a Buy rating and sixteen have issued a Hold rating to the company’s stock. According to data from MarketBeat, Docusign currently has an average rating of “Hold” and a consensus price target of $86.80.

Institutional Trading of Docusign

Several large investors have recently bought and sold shares of DOCU. HighTower Advisors LLC grew its stake in Docusign by 15.2% in the first quarter. HighTower Advisors LLC now owns 45,690 shares of the company’s stock worth $3,719,000 after purchasing an additional 6,013 shares in the last quarter. Aberdeen Group plc lifted its holdings in shares of Docusign by 130.0% in the first quarter. Aberdeen Group plc now owns 108,969 shares of the company’s stock valued at $8,870,000 after buying an additional 61,598 shares during the period. Ethic Inc. boosted its holdings in Docusign by 281.8% during the first quarter. Ethic Inc. now owns 14,485 shares of the company’s stock worth $1,198,000 after buying an additional 10,691 shares in the last quarter. Raymond James Financial Inc. raised its holdings in Docusign by 5.1% during the 1st quarter. Raymond James Financial Inc. now owns 449,139 shares of the company’s stock worth $36,560,000 after buying an additional 21,640 shares during the period. Finally, Corient IA LLC purchased a new position in shares of Docusign during the first quarter valued at $204,000. Institutional investors and hedge funds own 77.64% of the company’s stock.

Docusign Company Profile

DocuSign, Inc provides electronic signature solution in the United States and internationally. The company provides e-signature solution that enables sending and signing of agreements on various devices; Contract Lifecycle Management (CLM), which automates workflows across the entire agreement process; Document Generation streamlines the process of generating new, custom agreements; and Gen for Salesforce, which allows sales representatives to automatically generate agreements with a few clicks from within Salesforce.